Symbols / TRIB Stock $0.66 -2.32% Trinity Biotech plc

Healthcare • Medical Devices • Ireland • NMS
TRIB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. John Gillard
Exch · Country NMS · Ireland
Market Cap 13.45M
Enterprise Value 146.30M
Income -37.38M
Sales 43.78M
FCF (ttm) -11.20M
Book/sh -2.93
Cash/sh 0.25
Employees 287
Insider 10d —
IPO Oct 21, 1992
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.64
PEG 0.30
P/S 0.31
P/B -0.23
P/C —
EV/EBITDA -17.75
EV/Sales 3.34
Quick Ratio 0.11
Current Ratio 0.25
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -2.00
EPS next Y -1.03
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-07-01
Earnings (prior) 2025-07-01
ROA -5.72%
ROE —
ROIC —
Gross Margin 38.57%
Oper. Margin -9.98%
Profit Margin -85.36%
Shs Outstand 20.25M
Shs Float 16.22M
Insider Own 16.58%
Instit Own 5.30%
Short Float 1.21%
Short Ratio 2.19
Short Interest 239.69K
52W High 3.44
vs 52W High -80.69%
52W Low 0.50
vs 52W Low 32.84%
Beta 0.93
Impl. Vol. 50.00%
Rel Volume 0.97
Avg Volume 155.75K
Volume 150.97K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.68
Price $0.66
Change -2.32%
About

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a molecular diagnostics company for developing a non invasive urine based prognostic test for progression to aggressive prostate cancer. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.66
Latest analyst target
3. DCF / Fair value
$-9.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.66
Low
—
High
—
Mean
—
News
RSS: Latest TRIB news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
43.78
-28.87%
61.55
+8.31%
56.83
-9.10%
62.52
Operating Revenue
43.78
-28.87%
61.55
+8.31%
56.83
-9.10%
62.52
Cost Of Revenue
26.90
-32.95%
40.11
+7.31%
37.38
-17.39%
45.25
Reconciled Cost Of Revenue
26.90
-32.95%
40.11
+7.31%
37.38
-17.39%
45.25
Gross Profit
16.89
-21.24%
21.44
+10.24%
19.45
+12.64%
17.27
Operating Expense
28.30
-19.47%
35.15
-0.70%
35.39
+14.98%
30.78
Research And Development
3.63
-20.12%
4.54
+3.75%
4.38
+5.82%
4.14
Selling General And Administration
24.67
-14.37%
28.82
-7.50%
31.15
+15.45%
26.98
General And Administrative Expense
—
—
—
—
Other Gand A
—
—
—
—
Other Operating Expenses
—
1.79
+1394.93%
-0.14
+59.41%
-0.34
Total Expenses
55.20
-26.65%
75.26
+3.41%
72.78
-4.29%
76.03
Operating Income
-11.42
+16.70%
-13.70
+14.04%
-15.94
-17.98%
-13.51
Total Operating Income As Reported
-15.79
+25.40%
-21.16
+21.74%
-27.05
-39.77%
-19.35
EBITDA
-21.38
-26.47%
-16.91
+32.39%
-25.00
+16.42%
-29.91
Normalized EBITDA
-8.71
+33.03%
-13.01
-0.15%
-12.99
-18.67%
-10.95
Reconciled Depreciation
2.68
+43.91%
1.86
+4.95%
1.78
-23.83%
2.33
EBIT
-24.06
-28.20%
-18.77
+29.91%
-26.78
+16.96%
-32.25
Total Unusual Items
-12.67
-225.27%
-3.89
+67.58%
-12.01
+36.68%
-18.97
Total Unusual Items Excluding Goodwill
-12.67
-225.27%
-3.89
+67.58%
-12.01
+36.68%
-18.97
Special Income Charges
-12.67
-225.27%
-3.89
+67.58%
-12.01
-29.29%
-9.29
Other Special Charges
8.11
+578.29%
-1.70
-287.29%
0.91
-73.77%
3.45
Impairment Of Capital Assets
2.18
-1.40%
2.21
-77.01%
9.61
+79.30%
5.36
Restructuring And Mergern Acquisition
2.38
-43.03%
4.18
0.00
0.00
Write Off
0.00
+100.00%
-0.80
-153.33%
1.50
+211.20%
0.48
Net Income
-37.38
-17.58%
-31.79
-32.35%
-24.02
+41.43%
-41.01
Pretax Income
-37.18
-20.98%
-30.73
+16.78%
-36.93
+15.65%
-43.78
Net Non Operating Interest Income Expense
-13.10
+0.28%
-13.13
-46.28%
-8.98
+20.58%
-11.30
Interest Expense Non Operating
13.11
+9.65%
11.96
+17.86%
10.15
-12.00%
11.53
Net Interest Income
-13.10
+0.28%
-13.13
-46.28%
-8.98
+20.58%
-11.30
Interest Expense
13.11
+9.65%
11.96
+17.86%
10.15
-12.00%
11.53
Interest Income Non Operating
0.22
0.00
0.00
-100.00%
0.30
Interest Income
0.22
0.00
0.00
-100.00%
0.30
Other Income Expense
-12.67
-225.27%
-3.89
+67.57%
-12.01
+36.69%
-18.96
Other Non Operating Income Expenses
—
—
0.00
+0.00%
0.00
Gain On Sale Of Security
—
—
—
-9.68
Gain On Sale Of Business
—
—
—
—
Tax Provision
0.20
-59.05%
0.49
+923.73%
-0.06
+69.59%
-0.19
Tax Rate For Calcs
0.00
+0.00%
0.00
+7712.50%
0.00
-63.89%
0.00
Tax Effect Of Unusual Items
-1.58
-225.27%
-0.49
-2433.05%
-0.02
+77.14%
-0.08
Net Income Including Noncontrolling Interests
-37.38
-17.58%
-31.79
-32.35%
-24.02
+41.43%
-41.01
Net Income From Continuing Operation Net Minority Interest
-37.38
-19.73%
-31.22
+15.33%
-36.87
+15.41%
-43.59
Net Income From Continuing And Discontinued Operation
-37.38
-17.58%
-31.79
-32.35%
-24.02
+41.43%
-41.01
Net Income Continuous Operations
-37.38
-19.73%
-31.22
+15.33%
-36.87
+15.41%
-43.59
Net Income Discontinuous Operations
0.00
+100.00%
-0.57
-104.46%
12.85
+398.64%
2.58
Normalized Income
-26.29
+5.45%
-27.81
-11.78%
-24.88
-0.71%
-24.70
Net Income Common Stockholders
-37.38
-17.58%
-31.79
-32.35%
-24.02
+41.43%
-41.01
Diluted EPS
—
-1.77
+44.69%
-3.20
+47.37%
-6.08
Basic EPS
—
-1.77
+44.69%
-3.20
+47.37%
-6.08
Basic Average Shares
—
17.96
+134.61%
7.65
+13.46%
6.75
Diluted Average Shares
—
17.96
+101.78%
8.90
+31.92%
6.75
Diluted NI Availto Com Stockholders
-37.38
-17.58%
-31.79
-32.35%
-24.02
+41.43%
-41.01
Total Other Finance Cost
0.20
-82.76%
1.17
+200.09%
-1.17
-1682.43%
0.07
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
105.17
+1.82%
103.29
+73.79%
59.44
-35.47%
92.10
Current Assets
35.90
-12.70%
41.12
+5.34%
39.04
-16.34%
46.67
Cash Cash Equivalents And Short Term Investments
5.14
-0.56%
5.17
+39.99%
3.69
-43.89%
6.58
Cash And Cash Equivalents
5.14
-0.56%
5.17
+39.99%
3.69
-43.89%
6.58
Cash Equivalents
—
—
—
0.00
Cash Financial
5.14
-0.56%
5.17
+39.99%
3.69
-43.89%
6.58
Receivables
10.28
-29.59%
14.60
+9.14%
13.38
-14.52%
15.65
Accounts Receivable
9.36
-30.22%
13.42
+25.41%
10.70
-15.22%
12.62
Gross Accounts Receivable
10.45
-33.46%
15.70
+20.58%
13.02
-14.94%
15.31
Allowance For Doubtful Accounts Receivable
-1.09
+52.49%
-2.29
+1.64%
-2.32
+13.64%
-2.69
Other Receivables
0.34
-45.54%
0.63
-44.13%
1.12
-2.94%
1.16
Taxes Receivable
0.58
+3.21%
0.56
-64.08%
1.56
-16.94%
1.88
Inventory
18.83
-2.82%
19.37
-2.80%
19.93
-11.42%
22.50
Raw Materials
11.48
+14.48%
10.03
-0.21%
10.05
-16.88%
12.09
Work In Process
3.74
-25.08%
4.99
+10.92%
4.50
+13.93%
3.95
Finished Goods
3.60
-17.18%
4.35
-19.12%
5.38
-16.70%
6.46
Prepaid Assets
1.65
-16.42%
1.98
-2.80%
2.04
+5.38%
1.93
Other Current Assets
—
—
—
0.00
Total Non Current Assets
69.26
+11.42%
62.17
+204.82%
20.39
-55.11%
45.44
Net PPE
5.30
+14.74%
4.62
+144.24%
1.89
-66.70%
5.68
Gross PPE
72.83
+3.12%
70.62
+6.90%
66.07
+0.71%
65.61
Accumulated Depreciation
-67.52
-2.30%
-66.00
-2.85%
-64.18
-7.10%
-59.92
Properties
0.00
0.00
0.00
0.00
Land And Improvements
28.56
+6.63%
26.78
+10.37%
24.27
-1.68%
24.68
Machinery Furniture Equipment
41.44
+0.99%
41.03
+5.09%
39.04
+2.14%
38.22
Leases
2.83
+0.53%
2.81
+1.85%
2.76
+2.18%
2.70
Goodwill And Other Intangible Assets
56.99
+10.99%
51.34
+215.57%
16.27
-53.87%
35.27
Goodwill
13.97
+0.92%
13.84
0.00
-100.00%
12.54
Other Intangible Assets
43.02
+14.71%
37.50
+130.51%
16.27
-28.43%
22.73
Investments And Advances
2.77
+12.95%
2.46
0.00
—
Non Current Accounts Receivable
—
—
0.04
-57.14%
0.08
Non Current Deferred Assets
3.92
+10.44%
3.55
+79.90%
1.98
-53.18%
4.22
Non Current Deferred Taxes Assets
3.92
+10.44%
3.55
+79.90%
1.98
-53.18%
4.22
Other Non Current Assets
0.03
+0.00%
0.03
-34.88%
0.04
-21.82%
0.06
Total Liabilities Net Minority Interest
177.15
+27.93%
138.47
+66.06%
83.38
-11.56%
94.28
Current Liabilities
141.21
+339.97%
32.09
+113.47%
15.04
-13.29%
17.34
Payables And Accrued Expenses
29.48
+9.85%
26.84
+107.70%
12.92
-14.92%
15.19
Payables
12.55
-5.22%
13.24
+146.60%
5.37
-18.66%
6.60
Accounts Payable
11.48
+67.98%
6.83
+75.88%
3.88
-37.39%
6.21
Other Payable
0.41
-92.33%
5.38
+573.00%
0.80
—
Current Accrued Expenses
16.93
+24.53%
13.60
+80.05%
7.55
-12.03%
8.59
Pensionand Other Post Retirement Benefit Plans Current
0.38
+241.96%
0.11
+1.82%
0.11
+6.80%
0.10
Total Tax Payable
0.66
-35.68%
1.02
+49.56%
0.68
+72.73%
0.40
Income Tax Payable
0.35
-4.40%
0.36
+30.47%
0.28
+896.43%
0.03
Current Debt And Capital Lease Obligation
110.81
+4341.40%
2.50
+31.04%
1.90
+0.95%
1.89
Current Debt
108.22
+51435.71%
0.21
+0.00%
0.21
+0.00%
0.21
Other Current Borrowings
108.02
—
—
0.21
Current Capital Lease Obligation
2.59
+13.26%
2.29
+34.89%
1.69
+1.07%
1.68
Current Deferred Liabilities
0.19
-5.08%
0.20
+294.00%
0.05
-56.14%
0.11
Current Deferred Revenue
0.19
-5.08%
0.20
+294.00%
0.05
-56.14%
0.11
Total Non Current Liabilities Net Minority Interest
35.94
-66.22%
106.38
+55.64%
68.35
-11.17%
76.94
Long Term Debt And Capital Lease Obligation
27.17
-72.35%
98.27
+49.98%
65.52
-6.81%
70.31
Long Term Debt
16.33
-81.40%
87.79
+60.64%
54.65
-5.85%
58.05
Long Term Capital Lease Obligation
10.84
+3.46%
10.48
-3.63%
10.87
-11.37%
12.27
Long Term Provisions
0.78
+941.33%
0.07
—
—
Non Current Deferred Liabilities
4.67
+2.32%
4.56
+98.30%
2.30
-54.53%
5.06
Non Current Deferred Taxes Liabilities
4.67
+2.32%
4.56
+98.30%
2.30
-54.53%
5.06
Other Non Current Liabilities
—
1.81
—
—
Stockholders Equity
-71.98
-104.60%
-35.18
-46.90%
-23.95
-1000.60%
-2.18
Common Stock Equity
-71.98
-104.60%
-35.18
-46.90%
-23.95
-1000.60%
-2.18
Capital Stock
0.04
-99.05%
4.19
+112.47%
1.97
+0.46%
1.96
Common Stock
0.04
-99.05%
4.19
+112.47%
1.97
+0.46%
1.96
Share Issued
386.76
+4.04%
371.75
+124.13%
165.87
+0.53%
164.99
Ordinary Shares Number
374.21
+4.18%
359.19
+134.29%
153.31
+0.58%
152.43
Treasury Shares Number
12.56
0.00%
12.56
+0.00%
12.56
+0.00%
12.56
Additional Paid In Capital
63.80
+0.64%
63.40
+35.99%
46.62
+0.35%
46.46
Retained Earnings
-116.17
-46.83%
-79.12
-62.64%
-48.64
-82.22%
-26.70
Gains Losses Not Affecting Retained Earnings
-1.44
+73.52%
-5.44
+4.31%
-5.68
+0.11%
-5.69
Treasury Stock
24.92
+0.00%
24.92
+0.00%
24.92
+0.00%
24.92
Other Equity Adjustments
4.34
+18756.52%
0.02
+0.00%
0.02
-73.26%
0.09
Total Equity Gross Minority Interest
-71.98
-104.60%
-35.18
-46.90%
-23.95
-1000.60%
-2.18
Total Capitalization
-55.65
-205.78%
52.61
+71.36%
30.70
-45.05%
55.87
Working Capital
-105.31
-1266.32%
9.03
-62.39%
24.01
-18.15%
29.33
Invested Capital
52.57
-0.47%
52.82
+70.88%
30.91
-44.88%
56.08
Total Debt
137.98
+36.94%
100.76
+49.44%
67.43
-6.61%
72.20
Net Debt
119.42
+44.16%
82.83
+61.88%
51.17
-0.98%
51.68
Capital Lease Obligations
13.43
+5.22%
12.76
+1.56%
12.57
-9.88%
13.94
Net Tangible Assets
-128.97
-49.06%
-86.52
-115.13%
-40.22
-7.41%
-37.45
Tangible Book Value
-128.97
-49.06%
-86.52
-115.13%
-40.22
-7.41%
-37.45
Current Notes Payable
0.21
+0.00%
0.21
+0.00%
0.21
+0.00%
0.21
Current Provisions
0.34
-85.94%
2.45
+4808.00%
0.05
+0.00%
0.05
Derivative Product Liabilities
3.32
+100.24%
1.66
+215.21%
0.53
-66.48%
1.57
Financial Assets
0.25
+50.00%
0.17
-6.74%
0.18
+39.06%
0.13
Foreign Currency Translation Adjustments
-5.78
-5.79%
-5.46
+4.29%
-5.71
+1.19%
-5.78
Investmentin Financial Assets
2.77
+12.95%
2.46
0.00
—
Other Equity Interest
6.71
+0.00%
6.71
+0.00%
6.71
+0.00%
6.71
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-5.93
-41.47%
-4.19
+63.74%
-11.56
-1154.83%
-0.92
Cash Flow From Continuing Operating Activities
-5.93
-41.47%
-4.19
+63.74%
-11.56
-1154.83%
-0.92
Net Income From Continuing Operations
-37.38
-17.58%
-31.79
-32.35%
-24.02
+41.43%
-41.01
Depreciation Amortization Depletion
2.68
+43.91%
1.86
+4.95%
1.78
-23.83%
2.33
Depreciation
1.30
+92.44%
0.68
-18.77%
0.83
-41.06%
1.41
Amortization Cash Flow
1.39
+16.39%
1.19
+25.79%
0.95
+2.49%
0.92
Depreciation And Amortization
2.68
+43.91%
1.86
+4.95%
1.78
-23.83%
2.33
Amortization Of Intangibles
1.39
+16.39%
1.19
+25.79%
0.95
+2.49%
0.92
Other Non Cash Items
20.29
+80.07%
11.27
-3.17%
11.64
-52.90%
24.71
Stock Based Compensation
0.32
-75.38%
1.32
-36.39%
2.07
+17.89%
1.75
Provisionand Write Offof Assets
0.19
-48.20%
0.36
0.00
0.00
Asset Impairment Charge
2.18
-46.80%
4.09
-57.40%
9.61
+64.50%
5.84
Deferred Tax
0.20
-59.05%
0.49
+923.73%
-0.06
+69.27%
-0.19
Deferred Income Tax
0.20
-59.05%
0.49
+923.73%
-0.06
+69.27%
-0.19
Operating Gains Losses
-1.10
-209.11%
1.01
+108.09%
-12.48
-16764.86%
-0.07
Net Foreign Currency Exchange Gain Loss
-1.10
-209.11%
1.01
+324.37%
0.24
+413.16%
-0.08
Gain Loss On Sale Of PPE
—
0.00
0.00
-100.00%
0.00
Change In Working Capital
7.03
+13.61%
6.19
+1639.30%
-0.40
-107.02%
5.73
Change In Receivables
4.92
+307.77%
-2.37
-326.17%
1.05
+208.39%
-0.97
Change In Inventory
0.09
+105.17%
-1.74
-79.40%
-0.97
-10.72%
-0.88
Change In Payables And Accrued Expense
1.39
-83.01%
8.19
+395.59%
-2.77
-1629.83%
0.18
Change In Payable
1.39
-83.01%
8.19
+395.59%
-2.77
-1629.83%
0.18
Change In Other Working Capital
0.63
-70.23%
2.11
-7.77%
2.29
-69.00%
7.39
Investing Cash Flow
-6.22
+72.91%
-22.97
-192.78%
24.76
+514.19%
-5.98
Cash Flow From Continuing Investing Activities
-6.22
+72.91%
-22.97
-192.78%
24.76
+514.19%
-5.98
Net PPE Purchase And Sale
-0.09
+78.27%
-0.41
+49.56%
-0.80
+27.07%
-1.10
Purchase Of PPE
-0.09
+78.27%
-0.41
+49.56%
-0.80
+27.07%
-1.10
Capital Expenditure
-6.22
+38.17%
-10.06
-272.19%
-2.70
+54.76%
-5.98
Net Investment Purchase And Sale
0.00
0.00
+100.00%
-0.70
0.00
Purchase Of Investment
0.00
0.00
+100.00%
-0.70
0.00
Net Business Purchase And Sale
0.00
+100.00%
-12.90
-145.82%
28.16
0.00
Purchase Of Business
0.00
+100.00%
-12.90
0.00
0.00
Gain Loss On Sale Of Business
0.00
0.00
+100.00%
-12.72
0.00
Net Intangibles Purchase And Sale
-6.13
+36.48%
-9.66
-408.10%
-1.90
+61.01%
-4.88
Purchase Of Intangibles
-6.13
+36.48%
-9.66
-408.10%
-1.90
+61.01%
-4.88
Financing Cash Flow
12.05
-58.17%
28.81
+279.59%
-16.04
-30.19%
-12.32
Cash Flow From Continuing Financing Activities
12.05
-58.17%
28.81
+279.59%
-16.04
-30.19%
-12.32
Net Issuance Payments Of Debt
11.81
-57.31%
27.67
+475.58%
-7.37
+69.30%
-24.00
Issuance Of Debt
15.00
-50.29%
30.18
+503.52%
5.00
-95.00%
100.02
Repayment Of Debt
-3.19
-27.33%
-2.50
+79.76%
-12.37
+90.03%
-124.01
Long Term Debt Issuance
15.00
-50.29%
30.18
+503.52%
5.00
-95.00%
100.02
Long Term Debt Payments
-3.19
-27.33%
-2.50
+79.76%
-12.37
+66.83%
-37.28
Net Long Term Debt Issuance
11.81
-57.31%
27.67
+475.58%
-7.37
-111.75%
62.73
Short Term Debt Payments
—
0.00
0.00
+100.00%
-86.73
Net Short Term Debt Issuance
—
0.00
0.00
+100.00%
-86.73
Net Common Stock Issuance
0.55
-92.60%
7.39
0.00
-100.00%
25.34
Cash Dividends Paid
0.00
0.00
0.00
0.00
Net Other Financing Charges
—
—
-1.05
+81.68%
-5.74
Changes In Cash
-0.10
-106.06%
1.65
+158.07%
-2.84
+85.21%
-19.22
Effect Of Exchange Rate Changes
0.07
+140.57%
-0.17
-297.73%
-0.04
+60.71%
-0.11
Beginning Cash Position
5.17
+39.99%
3.69
-43.89%
6.58
-74.61%
25.91
End Cash Position
5.14
-0.56%
5.17
+39.99%
3.69
-43.89%
6.58
Free Cash Flow
-12.15
+14.75%
-14.26
+0.04%
-14.26
-106.74%
-6.90
Common Stock Issuance
0.55
-92.60%
7.39
0.00
-100.00%
25.34
Interest Paid CFF
-0.31
+95.08%
-6.25
+17.95%
-7.62
+3.71%
-7.92
Interest Paid CFO
—
—
0.00
0.00
Interest Received CFO
0.00
0.00
0.00
-100.00%
0.00
Issuance Of Capital Stock
0.55
-92.60%
7.39
0.00
-100.00%
25.34
Sale Of Business
0.00
0.00
-100.00%
28.16
0.00
Taxes Refund Paid
-0.35
-134.26%
1.01
+223.72%
0.31
+2180.00%
-0.01
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category